# US 2023/0065693 A1 · Reagents for massively parallel nucleic acid sequencing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0065693 A1
- Document ID: US20230065693A1
- Status: Published application
- Kind: A1
- Application number: 17/947,984
- Filed: 2022-09-19
- Published: 2023-03-02
- Earliest claimed: 2020-10-30
- Assignees: Element Biosciences, Inc.
- Applicants: Element Biosciences, Inc.
- Inventors: Sinan ARSLAN; Molly HE; Michael PREVITE; Ramreddy TIPPANA; Hua YU; William LIGHT; Junhua ZHAO
- Web page: https://patentgrep.com/patent/US20230065693A1

## CPC

- C12Q 1/6869: Methods for sequencing
- C12Q 1/6874: involving nucleic acid arrays, e.g. sequencing by hybridisation
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/6895: for plants, fungi or algae
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present disclosure provides compositions and methods that employ the compositions for conducting nucleic acid sequencing workflows, where the workflows include library preparation, immobilization and amplification of the library molecules to form immobilized template molecules, and sequencing the template molecules. In some embodiments, the compositions comprise reagents used to conduct nucleic acid sequencing workflows.

## Claims

### Claim 1

A method of analyzing a nucleic acid sequence, the method comprising:
(a) bringing the nucleic acid sequence in contact with a fluorescently-labeled nucleotide conjugate and a polymerizing enzyme under conditions sufficient to form a binding complex comprising (i) the polymerizing enzyme and (ii) a nucleotide of the nucleic acid sequence bound to a nucleotide moiety of the fluorescently-labeled nucleotide conjugate, wherein the binding complex persists for a persistence time of 1 second or more before it is removed;
(b) contacting the binding complex with an imaging reagent, wherein the imaging reagent comprises a photobleaching reducing agent; and
(c) obtaining a fluorescent image of the binding complex in a presence of the imaging reagent.

### Claim 2 (depends on 1)

The method of claim 1, wherein the photobleaching reducing agent comprises (i) ascorbic acid, (ii) Trolox, or (iii) a combination of the ascorbic acid and the Trolox.

### Claim 3 (depends on 2)

The method of claim 2, wherein in (c), the fluorescent image exhibits no residual fluorescent signal from the fluorescently-labeled nucleotide conjugate of the binding complex when (i) the photobleaching reducing agent comprises 50 millimolar (mM) of the ascorbate and 2 mM of the Trolox, wherein the Trolox is non-aged Trolox and (ii) the obtaining comprises performing a 90 second exposure by a laser having a power of between 75-200 milliwatt (mW).

### Claim 4 (depends on 2)

The method of claim 2, wherein the photobleaching reducing agent comprises ascorbic acid.

### Claim 5 (depends on 4)

The method of claim 4, wherein a concentration of the ascorbic acid is at least 20 millimolar (mM).

### Claim 6 (depends on 4)

The method of claim 4, wherein a concentration of the ascorbic acid is between about 10 millimolar (mM) and about 100 mM.

### Claim 7 (depends on 4)

The method of claim 4, wherein a concentration of the ascorbic acid is about millimolar (50 mM).

### Claim 8 (depends on 1)

The method of claim 1, further comprising bringing the nucleic acid sequence into contact with a second fluorescently-labeled nucleotide conjugate under conditions sufficient to form a second binding complex comprising a second nucleotide of the nucleic acid sequence bound to a second nucleotide moiety of the fluorescently-labeled nucleotide conjugate, wherein the nucleotide is adjacent to the second nucleotide in the nucleic acid sequence.

### Claim 9 (depends on 1)

The method of claim 1, wherein the nucleic acid sequence is comprised in a concatemer nucleic acid molecule comprising tandem repeats of the nucleic acid sequence.

### Claim 10 (depends on 1)

The method of claim 1, wherein the nucleic acid sequence further comprises at least one universal adapter sequence.

### Claim 11 (depends on 1)

The method of claim 1, wherein the fluorescently-labeled nucleotide conjugate comprises (i) a core, (ii) a plurality of the nucleotide moiety coupled to the core, and (ii) one or more fluorophores coupled to the core.

### Claim 12 (depends on 11)

The method of claim 11, wherein the fluorescently-labeled nucleotide conjugate further comprises a core attachment moiety linking the plurality of the nucleotide moiety to the core.

### Claim 13

The method of 11, wherein the nucleotide moiety is selected from the group consisting of dATP, dGTP, dCTP, dTTP and dUTP.

### Claim 14 (depends on 1)

The method of claim 1, further comprising bringing the nucleic acid sequence into contact with a plurality of fluorescently-labeled nucleotide conjugates comprising the fluorescently-labeled nucleotide conjugate and an additional fluorescently-labeled nucleotide conjugate, wherein the nucleotide moiety of the fluorescently-labeled nucleotide conjugate is different than an additional nucleotide moiety of the additional fluorescently-labeled nucleotide conjugate.

### Claim 15 (depends on 14)

The method of claim 14, wherein the additional nucleotide moiety is selected from the group consisting of dATP, dGTP, dCTP, dTTP and dUTP.

### Claim 16 (depends on 1)

The method of claim 1, wherein the nucleotide moiety comprises between about 3 and about 10 phosphate groups.

### Claim 17 (depends on 1)

The method of claim 1, wherein the nucleotide of the nucleic acid sequence comprises a removable chain terminating moiety.

### Claim 18 (depends on 17)

The method of claim 17, wherein the removable chain terminating moiety has a blocking moiety at the 3′ sugar position of the nucleotide configured to prevent incorporation of the nucleotide moiety into the nucleic acid sequence.

### Claim 19 (depends on 1)

The method of claim 1, wherein the polymerizing enzyme is a DNA polymerase.

### Claim 20 (depends on 1)

The method of claim 1, wherein the polymerizing enzyme lacks a detectable label.

### Claim 21 (depends on 1)

The method of claim 1, wherein the binding complex is immobilized to a surface of a support, and wherein the surface comprises a hydrophilic coating layer coupled thereto.

### Claim 22 (depends on 21)

The method of claim 21, wherein the image of the surface exhibits a contrast to noise ratio (CNR) that is greater than or equal to about 20 when the fluorescently-labeled nucleotide conjugate of the binding complex comprises a detectable label comprising Cyanine dye-3 (Cy3) and when the image of the surface is acquired using an inverted fluorescence microscope and a camera under non-signal saturating conditions while the surface is immersed in a buffer.

### Claim 23 (depends on 21)

The method of claim 21, wherein the hydrophilic coating layer comprises a water contact angle of less than 50 degrees.

### Claim 24 (depends on 21)

The method of claim 21, wherein a plurality of the nucleic acid sequence is immobilized to the surface, and wherein a surface density of the plurality of the nucleic acid sequence comprises about 103 molecules/millimeter (mm)2 to about 5×105 molecules/mm2.

### Claim 25 (depends on 1)

The method of claim 1, wherein the imaging reagent comprises a non-catalytic divalent cation that inhibits incorporation of the nucleotide moiety of the fluorescently-labeled nucleotide conjugate.

### Claim 26 (depends on 25)

The method of claim 25, wherein the non-catalytic divalent cation comprises strontium, barium, scandium, titanium, calcium, vanadium, chromium, iron, cobalt, nickel, copper, zinc, gallium, germanium, arsenic, selenium, rhodium, europium, tin or terbium ions.

### Claim 27 (depends on 1)

The method of claim 1, wherein the nucleic acid sequence comprises a template nucleic acid sequence for a sequencing reaction and at least one universal adaptor sequence.

### Claim 28 (depends on 1)

The method of claim 1, wherein the imaging reagent further comprises methyl viologen, Tris-HCl EDTA, NaCl, Triton X-100, sucrose, strontium acetate or glycerol, or any combination thereof.

### Claim 29 (depends on 1)

The method of claim 1, wherein said persistence time is more than 1 second.

### Claim 30 (depends on 1)

The method of claim 1, further comprising identifying the nucleotide by analyzing the image obtained in (c).
